Timeline
![](https://research.pasteur.fr/wp-content/uploads/2015/05/research_pasteur-mathieu-mateo-mathieu-150x150.jpg)
Mathieu Mateo
Assistant Professor
12 Sep 2023
publication
Hemostasis defects underlying the hemorrhagic syndrome caused by Mammarenaviruses in a cynomolgus macaque model.
Read more11 Mar 2023
publication
Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys.
Read more01 Jan 2023
publication
A MOPEVAC multivalent vaccine induces sterile protection against New World arenaviruses in non-human primates.
Read more01 Dec 2022
publication
Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys.
Read more09 Jun 2021
publication
A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains.
Read more04 Jan 2021
publication
Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques.
Read more01 Dec 2020
publication
Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus.
Read more01 May 2020
publication
Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials.
Read more03 Jan 2020
01 Dec 2019
publication
A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast Milk.
Read more02 Oct 2019
publication
Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.
Read more01 Sep 2019
23 Mar 2019
21 Mar 2019
publication
Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus
Read more10 Jan 2019
01 Nov 2018
publication
Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells.
Read more01 Oct 2018
publication
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies
Read more29 May 2018
publication
A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins
Read more28 Sep 2017
publication
Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs
Read more15 Jun 2017
publication
Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea
Read more23 Mar 2017
publication
Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea
Read more23 Feb 2017
publication
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
Read more14 Jan 2017
publication
Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study
Read more18 Dec 2016
14 Nov 2016
03 May 2016
publication
New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors
Read more05 Apr 2016
publication
Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
Read more01 Mar 2016
publication
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
Read more07 Jan 2016
16 Dec 2015
21 Jul 2015
publication
Severe Ebola Virus Infection With Encephalopathy: Evidence for Direct Virus Involvement
Read more19 Jul 2015
03 Jul 2015
11 May 2015
06 Feb 2015
publication
Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus
Read more01 Jan 2015
publication
Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014
Read more24 Nov 2014
publication
Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014
Read more19 Nov 2014
24 Sep 2014
publication
Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response
Read more24 Sep 2014
publication
The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses
Read more16 Apr 2014
09 Jan 2014
publication
Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever
Read more05 Nov 2012
01 Jul 2012
publication
NK cells are strongly activated by Lassa and Mopeia virus-infected human macrophages in vitro but do not mediate virus suppression
Read more31 Aug 2011
publication
Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages
Read more01 Jun 2011
publication
Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus
Read more09 Feb 2011
05 Oct 2010
publication
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis
Read more01 Oct 2010
18 Mar 2009
publication
Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys
Read more20 Mar 2006
publication
Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages
Read more01 Jul 2005
01 Oct 2004
publication
Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection
Read more01 Mar 2004
publication
Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells
Read more01 Dec 2003